The vaccine not only reduced costs, but increased the number of healthy days of life for the elderly. Nichol et al. In addition, revaccination is recommended in persons aged 65 and older if they received a vaccination five or more years previous, and were less than 65 years of age at time of vaccination. A new, more immunogenic protein conjugate vaccine is in development and should be available within a year or so. Take a look.
Good evidence exists to support vaccination.
Tis the season. H. Edward Davidson, PharmD Norfolk, Virginia References 1. Centers for Disease Control and Prevention. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.